049960 — Cell Biotech Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩83bn
- KR₩14bn
- KR₩54bn
- 95
- 76
- 70
- 96
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 59,224 | 54,887 | 57,834 | 65,368 | 70,332 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6,562 | 5,826 | 5,217 | 5,336 | 6,397 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 69,258 | 64,913 | 67,519 | 75,655 | 81,929 |
Net Property, Plant And Equipment | 36,065 | 36,602 | 34,057 | 33,638 | 32,937 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 108,303 | 105,301 | 112,877 | 115,839 | 117,641 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,189 | 4,630 | 5,766 | 7,389 | 4,821 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Liabilities | 4,701 | 5,317 | 6,189 | 7,747 | 5,755 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 103,602 | 99,985 | 106,687 | 108,092 | 111,885 |
Total Liabilities & Shareholders' Equity | 108,303 | 105,301 | 112,877 | 115,839 | 117,641 |
Total Common Shares Outstanding |